Abstract
Aim. To perform a comparative analysis of the safety and efficacy of intravitreal injection (IVI) of ranibizumab and aflibercept with simultaneous phacoemulsification of cataract (FEC) and implantation of an intraocular lens (IOL) in patients with a combination of neovascular AMD and senile cataract. Methods. A comparative study was performed in 52 patients. IVI of ranibizumab and aflibercept was carried out by random sampling. Methods of clinical, OCT morphometric and immunological examination of tear in dynamics were used. Results. On the 31st day of follow-up, there was an increase in BCVA by an average of 3 lines, a decrease in the thickness of the retina in the macula the height and extent of subretinal fluid and pigment epithelium detachment, according to OCT. A decrease in the concentration of VEGF and TNFαwas detected in the tear. There was no statistically significant difference between ranibizumab and aflibercept. Conclusion. Simultaneous cataract surgery and administration of anti-VEGF drugs is an effective and safe method of treatment in patients with combined pathology. Key words: cataract surgery; neovascular age-related macular degeneration; anti-VEGF drugs; ranibizumab; aflibercept.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
